These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 36484817)

  • 1. What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?
    Baboudjian M; Roubaud G; Fromont G; Gauthé M; Beauval JB; Barret E; Brureau L; Créhange G; Dariane C; Fiard G; Mathieu R; Ruffion A; Rouprêt M; Renard-Penna R; Sargos P; Ploussard G;
    World J Urol; 2023 Aug; 41(8):2033-2041. PubMed ID: 36484817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
    Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
    Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cytoreductive radical prostatectomy in metastatic prostate cancer.
    Vladimír Š; Zuzana S; Hana Š
    Klin Onkol; 2022; 35(1):55-62. PubMed ID: 35236082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Radiotherapy for local disease in metastatic prostate cancer.].
    Cambeiro M; Calvo FA
    Arch Esp Urol; 2018 Mar; 71(3):298-305. PubMed ID: 29633951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer.
    Grisay G; Lavaud P; Fizazi K
    Curr Oncol Rep; 2024 May; 26(5):488-495. PubMed ID: 38592590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?
    Cahill EM; Pfail JL; Fu MZ; Saraiya B; Mayer T; Stephenson RD; Ennis RD; Hathout L; Deek MP; Ghodoussipour S; Jang TL
    Curr Urol Rep; 2023 Jul; 24(7):299-306. PubMed ID: 37017928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncological and perioperative outcomes of surgery with or without metastasis-directed therapy as part of a multimodal treatment in men with de-novo oligometastatic prostate cancer.
    Pellegrino A; Gandaglia G; de Angelis M; Fallara G; Mazzone E; Stabile A; Pellegrino F; Robesti D; Leni R; Scuderi S; Cucchiara V; Cirulli GO; Barletta F; Montorsi F; Briganti A
    World J Urol; 2023 Aug; 41(8):2069-2076. PubMed ID: 37326656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastasis-directed therapy in oligometastatic prostate cancer.
    Miszczyk M; Soeterik T; Marra G; Matsukawa A; Shariat SF
    Curr Opin Urol; 2024 May; 34(3):178-182. PubMed ID: 38426229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?
    Slaoui A; Albisinni S; Aoun F; Assenmacher G; Al Hajj Obeid W; Diamand R; Regragui S; Touzani A; Bakar A; Mesfioui A; Karmouni T; Ameur A; Elkhader K; Koutani A; Ibnattya A; Roumeguere T; Peltier A
    World J Urol; 2019 Nov; 37(11):2343-2353. PubMed ID: 30706122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapy.
    Wenzel M; Garcia CC; Hoeh B; Jorias C; Humke C; Koll F; Tselis N; Rödel C; Graefen M; Tilki D; Chun FKH; Mandel P
    Prostate; 2023 Oct; 83(14):1365-1372. PubMed ID: 37464963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review.
    Vanden Berg RNW; Zilli T; Achard V; Dorff T; Abern M
    Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):702-711. PubMed ID: 37422523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis.
    Ciccarese C; Iacovelli R; Sternberg CN; Gillessen S; Tortora G; Fizazi K
    Eur J Cancer; 2022 Sep; 173():276-284. PubMed ID: 35964470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
    Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF
    J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial.
    Dai B; Zhang S; Wan FN; Wang HK; Zhang JY; Wang QF; Kong YY; Ma XJ; Mo M; Zhu Y; Qin XJ; Lin GW; Ye DW
    Eur Urol Oncol; 2022 Oct; 5(5):519-525. PubMed ID: 35780048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer.
    Ranasinghe W; Chapin BF; Kim IY; Sooriakumaran P; Lawrentschuk N
    BJU Int; 2020 Jun; 125(6):792-800. PubMed ID: 32176456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer.
    Jalfon MJ; Sakhalkar OV; Lokeshwar SD; Marks VA; Choksi AU; Klaassen Z; Leapman MS; Kim IY
    Curr Urol Rep; 2023 Oct; 24(10):455-461. PubMed ID: 37369828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.
    Weiner AB; Nettey OS; Morgans AK
    Curr Treat Options Oncol; 2019 Jul; 20(9):69. PubMed ID: 31286275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
    Fizazi K; Foulon S; Carles J; Roubaud G; McDermott R; Fléchon A; Tombal B; Supiot S; Berthold D; Ronchin P; Kacso G; Gravis G; Calabro F; Berdah JF; Hasbini A; Silva M; Thiery-Vuillemin A; Latorzeff I; Mourey L; Laguerre B; Abadie-Lacourtoisie S; Martin E; El Kouri C; Escande A; Rosello A; Magne N; Schlurmann F; Priou F; Chand-Fouche ME; Freixa SV; Jamaluddin M; Rieger I; Bossi A;
    Lancet; 2022 Apr; 399(10336):1695-1707. PubMed ID: 35405085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.